— Conference call and webcast to be held at 8:30 a.m. EDT — BOSTON , Sept. 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that topline results from the PEDFIC 1 Phase 3

‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒ BOSTON , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators,

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials   — —  Enrolled first biliary atresia patients in second odevixibat pivotal study — —  Completed two financing transactions to secure cash into beginning of 2022 — —  Management to host conference call and webcast today at

BOSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will participate in a fireside chat presentation

—  Conference call and webcast to be held at 10:00 a.m. ET   —  BOSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call

— Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease — BOSTON , July 20, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company

— BOLD is first-ever pivotal trial for biliary atresia — — Trial expands odevixibat’s development program into second rare cholestatic liver disease — BOSTON , July 14, 2020 (GLOBE NEWSWIRE) --   Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing

BOSTON , June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a Key Opinion Leader (KOL) call on clinical outcome assessments (COAs) on Tuesday, June

— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital —   — Initial draw down of $10M on debt facility of up to $80M with Hercules Capital — BOSTON , June 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.

BOSTON , May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present via webcast at the 2020 Jefferies